Chembio to Present at the B. Riley 13th Annual Investor Conference

Chembio to Present at the B. Riley 13th Annual Investor Conference

MEDFORD, NY, May 17, 2012 (MARKETWIRE via COMTEX) --Chembio Diagnostics, Inc. (OTCQB: CEMI) (PINKSHEETS: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, today announced that its Chief Executive Officer, Lawrence Seibert will present at the B. Riley 13th Annual Investor Conference at 2:00 p.m. Pacific time on Monday, May 21, 2012. The conference is being held at the Loews Santa Monica Beach Hotel.

Interested parties can access a live audio webcast of the Company's presentation at http://www.webcastregister.com/briley/2012/register/CEMI and at www.chembio.com. An archived presentation will be available on the Company's website for 30 days.

Information about B. Riley & Company and the investor conference can be found at www.brileyco.com.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Inverness Medical Innovations, Inc. Chembio markets its HIV STAT-PAK^® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP^®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP^®. Headquartered in Medford, NY, with approximately 100 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed a review or audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contacts:
Company:
Susan Norcott
631-924-1135 x125
snorcott@chembio.com

Investor Relations:
LHA
Anne-Marie Fields
Vice President
(212) 838-3777
afields@lhai.com
@LHA_IR_PR

SOURCE: Chembio Diagnostics, Inc.

mailto:snorcott@chembio.com
mailto:afields@lhai.com